What is the prevalence of the HLA-B*5701 allele?

1. Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, et al. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med. 2013. 52(7):735-44. [Medline].

2. Kumar P, DeJesus E, Huhn G, Sloan L, Small CB, Edelstein H, et al. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis. 2013 Jun 7. 13:269. [Medline]. [Full Text].

3. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001 Oct. 23(10):1603-14. [Medline].

4. Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008 Jun. 28(6):822-32. [Medline].

5. Zhang Y, Mei H, Wang Q, Xie J, Lv J, Pan X, et al. Peptide binding specificities of HLA-B*5701 and B*5801. Sci China Life Sci. 2012 Sep. 55(9):818-25. [Medline].

6. Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis. 2017 Apr 11. 17 (1):256. [Medline]. [Full Text].

7. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7. 358(6):568-79. [Medline].

8. Dean L, Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, et al. Abacavir Therapy and HLA-B*57:01 Genotype. April 18, 2018. [Medline]. [Full Text].

9. [Guideline] Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo.nih.gov. Available at https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/37/whats-new-in-the-guidelines-. October 25, 2018; Accessed: November 15, 2018.

10. [Guideline] Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24. 320 (4):379-396. [Medline].

11. [Guideline] Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther. 2014 May. 95 (5):499-500. [Medline]. [Full Text].

12. To SW, Chen JH, Wong KH, Chan KC, Tsang OT, Yam WC. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?. Int J STD AIDS. 2013 Jan. 24(1):50-2. [Medline].

13. Barbarino JM, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul. 10 (4):e1417. [Medline]. [Full Text].

14. HLA B*5701 status, disease progression, and response to antiretroviral therapy. AIDS. 2013 Oct 23. 27(16):2587-92. [Medline]. [Full Text].

Ali Torkamani, PhD Director of Genome Informatics and Drug Discovery, The Scripps Translational Science Institute; Assistant Professor of Integrative Structural and Computational Biology, The Scripps Research Institute

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Vivid Genomics, Seqster Inc.<br/>Serve(d) as a speaker or a member of a speakers bureau for: Illumina<br/>Received research grant from: National Institutes of Health<br/>Received income in an amount equal to or greater than $250 from: Illumina.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.